Lmr Partners LLP Allakos Inc. Transaction History

Lmr Partners LLP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.6 - $6.14 $32,900 - $77,695	12,654 New	12,654 $40,000
Q1 2022 May 16, 2022	SELL	$5.08 - $9.81 $256,540 - $495,405	-50,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $431,775 - $5.65 Million	50,500 New	50,500 $494,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $108M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.